Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 6/20 | 0.34 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.33 |
| ▸ | CBFB | Q13951 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413370 | 1.00 | MTOR (0.42) | MTORPDE10AMEN1KMT2ANPC1 | |
| SCHEMBL20792222 | 0.85 | MTOR (0.46) | MTORPDE10AMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL30412872 | 0.84 | MTOR (0.45) | MTORPDE10AMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL22321399 | 0.84 | MTOR (0.45) | MTORPDE10AMEN1KMT2ANPC1 | |
| SCHEMBL30410997 | 0.80 | MTOR (0.48) | MTORPDE10AMEN1KMT2ANPC1 | |
| SCHEMBL20764736 | 0.80 | MTOR (0.48) | MTORPDE10AMEN1KMT2ANPC1 | |
| SCHEMBL30412413 | 0.78 | ITGA5 (0.41) | MTORMEN1KMT2ANPC1RAB9A | |
| SCHEMBL20764657 | 0.78 | ITGA5 (0.41) | MTORMEN1KMT2ANPC1RAB9A | |
| SCHEMBL20743025 | 0.77 | MTOR (0.49) | MTORMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19283638 | 0.75 | MTOR (0.46) | MTORMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111372928-B | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | disclosed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | disclosed |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-08-13 | — | — | US | disclosed |
| CN-111372928-A | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3672953-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | MTOR 1765/4885PDE10A 1099/4885MEN1 2010/4885 |
| US-11168074-B2 | Potassium channel inhibitors | KCNN2, KCNJ2, KCNN1 | MTOR 1498/4885PDE10A 1228/4885MEN1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.